sponsored
PatientsVille.com Logo

PatientsVille

Follistim Medical Research Studies

Up-to-date List of Follistim Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Follistim Medical Research Studies

Rank Status Study
1 Recruiting Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism
Condition: Infertility
Interventions: Drug: Lutropin alfa;   Drug: Follitropin alfa and Lutropin alfa
Outcome Measures: number of follicles;   Size of follicle;   Endometrial thickness;   number of oocytes retrieved;   Fertilization rate;   Biochemical pregnancy rate;   Clinical pregnancy rate;   Implantation rate
2 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
Condition: Infertility
Interventions: Drug: Pergoveris®;   Drug: GONAL-f®;   Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Outcome Measures: Total number of retrieved oocytes;   Ongoing pregnancy rate;   Live birth rate;   Embryo implantation rate;   Clinical pregnancy rate;   Biochemical pregnancy rate
3 Recruiting A Phase III Study to Compare Efficacy and Safety of AFOLIA vs. Gonal-f® in Infertile Women 35 to 42 Years of Age Undergoing in Vitro Fertilization (IVF)
Condition: Infertility
Interventions: Drug: Gonal-f;   Drug: AFOLIA
Outcome Measures: Clinical pregnancy;   Immunogenicity;   Local and systemic adverse events;   Pregnancy outcome
4 Not yet recruiting Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
Condition: Egg Donation
Interventions: Drug: Follistim;   Drug: Ganirelix;   Drug: Menotropins;   Drug: Leuprolide;   Procedure: Transvaginal ultrasound guided needle aspiration of oocytes
Outcome Measures: number of mature oocytes recovered and cryopreserved.;   1) #Days of ovarian stimulation to GnRH agonist trigger.;   2) Peak serum estradiol level on day of GnRH agonist trigger;   Number of follicles >15 mm average diameter on day of GnRH agonist trigger
5 Recruiting Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1
Condition: Infertility
Interventions: Drug: FE 999049;   Drug: Follitropin Alfa (Gonal-F)
Outcome Measures: Ongoing pregnancy rate;   Ongoing implantation rate;   Vital pregnancy rate;   Implantation rate;   Proportion of subjects with extreme ovarian responses, defined as <4, ≥15 or ≥20 oocytes retrieved;   Proportion of subjects with early OHSS (ovarian hyperstimulation syndrome) and/or preventive interventions for early OHSS;   Proportion of subjects with cycle cancellation due to poor ovarian response or excessive ovarian response;   Number of oocytes retrieved;   Proportion of subjects with <4, 4-7, 8-14, 15-19 and ≥20 oocytes retrieved;   Percentage of metaphase II oocytes (for subjects inseminated using ICSI);   Fertilisation rate;   Quality of embryos;   Quality of blastocysts;   Total gonadotropin dose;   Number of stimulation days;   Proportion of subjects with investigator-requested gonadotropin dose adjustments;   Frequency of injection site reactions (redness, pain, itching, swelling and bruising) assessed by the subject during the stimulation period;   Abdominal discomfort related to controlled ovarian stimulation as assessed by a visual analogue scale;   Changes in body weight;   Changes in maximum abdominal circumference;   Proportion of subjects with treatment-induced anti-FSH antibodies;   Proportion of subjects with late OHSS;   Technical malfunctions of the administration pen
6 Recruiting Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
Condition: Infertility
Interventions: Drug: Highly Purified Urofollitropin;   Drug: Recombinant Human Follitropin Alfa
Outcome Measures: The number of retrieved oocytes per cycle;   The follicles development;   The fertilization rate;   Implantation rate;   Cycle cancellation rate;   The positive serum β-hCG/hCG rate;   The clinical pregnancy rate;   The ongoing pregnancy rate;   Total gonadotropin dose administered and the duration of gonadotropin treatment;   Serum E2 (Estradiol) concentrations;   Frequency and severity of adverse events;   Frequency and severity of injection site reactions
7 Recruiting Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females
Condition: Anovulation
Interventions: Drug: Highly Purified Urofollitropin;   Drug: Recombinant Human Follitropin Alfa
Outcome Measures: The ovulation rate defined as the percentage of subjects who present ovulation;   The positive serum progesterone rate;   The positive serum β-hCG/hCG rate;   The clinical pregnancy rate;   The ongoing pregnancy rate;   The follicular development;   Endometrial thickness;   Total FSH (Follicle-stimulating hormone) dose administered;   Number of FSH treatment days;   Frequency and severity of adverse events;   Frequency and severity of injection site reactions;   Serum estradiol (E2) levels
8 Recruiting Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation
Condition: Infertility
Interventions: Drug: corifollitropin alfa;   Drug: recombinant follicle stimulating hormone (FSH)
Outcome Measures: Ongoing pregnancy rate;   Clinical pregnancy rate cancellation rate miscarriage rate ectopic pregnancy rate
9 Recruiting Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment
Condition: Infertility, Female
Interventions: Drug: fostimon;   Drug: puregon
Outcome Measure: Embryo quality
10 Recruiting FSH in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles
Condition: Infertility
Interventions: Drug: Urofollitrophin;   Drug: Follitrophin alpha
Outcome Measures: Clinical pregnancy rate;   Number of follicles >16 mm on the day of hCG injection;   Total number of oocytes retrieved;   Fertilization rate;   Embryo quality;   Positive serum pregnancy test;   Delivery rate;   Cumulative pregnancy rate
11 Recruiting A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
Condition: Infertility
Intervention:
Outcome Measures: Frequency and severity of all adverse events regardless of the causal relationship to Pergoveris®;   Clinical pregnancy;   Percentage of patients with more than one follicle greater than 17mm on day of human chorionic gonadotrophin (HCG) administration
12 Recruiting Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound;   Drug: recombinant human chorionic gonadotropin;   Drug: Recombinant follicle stimulating hormone;   Drug: Dexamethasone;   Drug: Adrenocorticotropin;   Drug: Glucose
Outcome Measures: 17-hydroxyprogesterone responses to hCG with and without FSH in PCOS women and normal controls;   Follicle count on 3-D Ultrasound in PCOS women and normal controls;   Adrenal androgen response to ACTH in PCOS women and normal controls;   17-hydroxyprogesterone response to hCG in the setting of reduced insulin secretion in PCOS women
13 Recruiting Predicting Ovarian Response in Artificial Insemination With Low Stimulation
Condition: Subfertility
Intervention: Drug: Follicle Stimulating Hormone
Outcome Measures: To assess the relationship between AMH serum levels and ovarian response;   To assess the relationship between age, weight, BMI, smoking, AFC, FSH/E2 on CD3 and ovarian response;   Pregnancy rate per started cycle.;   Multiple pregnancy rate per started cycle.;   Miscarriage rate per started cycle.;   Cancellation rate per stimulated cycle
14 Unknown  Ovarian Stimulation: Inositol and Melatonin
Condition: Infertility
Interventions: Drug: Recombinant FSH (rFSH);   Dietary Supplement: rFSH + Inositol + Melatonin
Outcome Measures: Total oocyte number;   Number of clinical pregnancies;   Live birth rate
15 Recruiting Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Conditions: Anovulation;   Oligo-ovulation;   Hypothalamic-pituitary Dysfunction;   Polycystic Ovarian Syndrome
Interventions: Drug: MSJ-0011;   Drug: urinary hCG
Outcome Measures: Title: Percentage of Participants Who Ovulated, defined as mid-luteal serum progesterone levels of >= 5 ng/mL or a clinical pregnancy;   Title: Percentage of Participants Who Ovulated, defined as mid-luteal serum progesterone levels of >= 9.4 ng/mL or a clinical pregnancy;   Mid-luteal Endometrial Thickness;   Percentage of Participants Who Had a Biochemical Pregnancy;   Percentage of Participants Who Had a Clinical Pregnancy
16 Unknown  Efficacy of a Pharmacogenetic Controlled Ovarian Stimulation Protocol Based on Follicle Stimulating Hormone Receptor (FSHR) Genotype Status
Condition: Sterility
Intervention: Drug: follicle stimulating hormone
Outcome Measures: clinical pregnancy rate;   follicle count, cycle cancellation rate, poor responder rate
17 Unknown  Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
Condition: In Vitro Fertilization
Interventions: Drug: Growth Hormone;   Drug: Patch protocol
Outcome Measures: number of mature oocytes retrieved;   duration of stimulation;   gonadotropin requirements;   number of cumulus-oocyte complexes retrieved;   number of fertilized oocytes;   proportion of patients reaching embryo transfer;   implantation rate;   clinical pregnancy rate
18 Unknown  Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH
Condition: Aneuploidy Rate
Interventions: Procedure: Stimulation with human FSH;   Procedure: Stimulation with recombinant FSH
Outcome Measures: Aneuploidy Rate;   Oocyte morphology;   Outcome rates (implantation, pregnancy and miscarriage rate)
19 Recruiting Embryo Kinetics and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH
Condition: Embryo Kinetics
Interventions: Procedure: Stimulation with human FSH;   Procedure: Stimulation with recombinant FSH
Outcome Measures: time of cell cleavage;   Embryo and oocyte morphology;   Outcome rates (implantation, pregnancy and miscarriage rate)
20 Not yet recruiting Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders
Condition: Infertility
Interventions: Other: mild stimulation protocol;   Other: controlled ovarian stimulation
Outcome Measures: clinical pregnancy rate;   live birth rate;   Number of oocytes retrieved;   Number of transferrable embryo;   normal fertilization rate;   implantation rate;   ongoing pregnancy rate;   Total dose of recombinant FSH consumption;   length of stimulation;   serum estradiol level;   serum LH level;   serum progesterone level;   serum FSH level;   FSH level in follicular fluid;   LH level in follicular fluid;   Estradiol level in the follicular fluid;   progesterone level in follicular fluid;   testerone level in the follicular fluid;   anti-müllerian hormone (AMH)level in follicular fluid;   Ovarian Hyperstimulation Syndrome (OHSS) rate

These studies may lead to new treatments and are adding insight into Follistim etiology and treatment.

A major focus of Follistim research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Follistim